Heart transplant is a scary and serious surgery with a high cost, but for patients with heart failure it can be the only ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational ...

Canaccord Genuity has downgraded Pliant (PLRX) to hold following news that the company has paused a clinical trial for its ...

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...

Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...

The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a ...